ISOFOL MEDICAL AB (PUBL)

# YEAR-END REPORT 2024

*Isofol issues all its reports in Swedish language and this report has been translated into English. In the event of differences between the two, the Swedish version shall apply.*

# Positive feedback and strengthened partner commitment

## SIGNIFICANT EVENTS DURING THE FOURTH QUARTER

- On October 23, the company announced that a Late Breaking Abstract regarding the drug candidate arfolitixorin was to be presented as a poster at ENA 2024 in Spain. The poster describes dose-dependent cytotoxic effects and increased activity of arfolitixorin at higher doses in combination with 5-FU.
- On November 20, the company presented an operational update during the investor meeting that took place in Gothenburg, and which was also available digitally via link. The company presented the evidence platform that forms the basis for the upcoming clinical study, the intended study design for the phase Ib/II study, and an update on the commercial potential of arfolitixorin.
- On November 21, the company announced that the investigator-initiated Modelle study, which evaluated the effect of arfolitixorin at the tissue level, has been published in the scientific journal BJC Reports. The study showed dose-dependent TS inhibition with arfolitixorin.
- On December 18, it was announced that the company's Japanese partner Solasia Pharma K.K. has made a strategic decision to include Japanese patients in the Phase II part of the upcoming Phase Ib/II clinical study of arfolitixorin in patients with metastatic colorectal cancer.

## SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- On January 27, 2025, Isofol announced that a post-hoc per protocol analysis of the AGENT study, conducted by an external expert committee, has been published as an abstract at ASCO-GI in the USA. The study shows significantly better effect of arfolitixorin in important regions.

For other significant events during the year, see previously published quarterly reports.

### Isofol is developing the cancer drug candidate arfolitixorin

Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with new dosing regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) handlas på Nasdaq Stockholm.

## FINANCIAL INFORMATION

### Fourth quarter, October-December 2024

- Net revenue amounted to kSEK 0 (0)
- The result for the period amounted to kSEK -13,102 (-8,883)
- Earnings per share amounted to SEK -0.08 (-0.05)
- Cash and cash equivalents on December 31 amounted to kSEK 96,157 (138,148)

### January-December 2024

- Net revenue amounted to kSEK 0 (721)
- The result for the period amounted to kSEK -43,488 (-37,071)
- Earnings per share amounted to SEK -0.27 (-0.23)
- The Board of Directors proposes that no dividend will be paid for the 2024 financial year

| KEY FIGURES kSEK | 2024 Oct-Dec | 2023 Oct-Dec | 2024 Jan-Dec | 2023 Jan-Dec |
|---|---|---|---|---|
| Net revenue | - | - | - | 721 |
| Result for the period | -13,102 | -8,883 | -43,488 | -37,071 |
| Earnings per share (SEK) | -0.08 | -0.05 | -0.27 | -0.23 |
| Cash and cash equivalents | 96,157 | 138,148 | 96,157 | 138,148 |

# Positive feedback and strengthened partner commitment as we approach the clinical study of arfolitixorin

Ahead of initiating the clinical study to evaluate our drug candidate arfolitixorin as a new potential treatment for metastatic colorectal cancer, we have received positive feedback on the study design from the German regulatory authority as well as a strong commitment from our Japanese partner Solasia Pharma K.K. At our November investor meeting, we provided an operational update and presented an evidence platform that forms the basis for the study design and enhances the probability of achieving positive results. We also confirmed arfolitixorin's commercial potential through a market analysis indicating blockbuster potential in the crucial U.S. market. Now, only the final preparations remain before we can start patient recruitment in collaboration with Charité – Universitätsmedizin Berlin.

*We move beyond 2024 with strengthened conviction and renewed energy as we enter the next phase in the company's development: launching the clinical study*

Petter Segelman Lindqvist,
CEO, Isofol Medical AB (publ)

## Positive feedback on the study design

During the fourth quarter, we have had an intense focus on finalizing the remaining preparations before the new phase Ib/II study can be initiated. Before the end of the year, we received positive feedback from the German regulatory authority, BfArM, to initiate the study and we are now finalizing discussions on the definitive design of the dose cohorts before we are ready to start the study. While we await final study approval, the positive feedback from the authority validates the study design and strengthens both us and our partners in our continued development work.

## Plans to expand the study to Japan

At year-end, it was announced that our Japanese partner Solasia has made a strategic decision to actively participate in the second part of the clinical Phase Ib/II-study. In parallel with the initiation of the first phase with Charité, Isofol and Solasia will jointly prepare for the second part of the study with the aim of enrolling patients in Japan during 2026. The expansion of the study to Japan means an increased number of patients and diversifies the patient population, creating better conditions for future regulatory processes both in Japan and in other markets.

Looking specifically at our planned activities in Japan, the focus for 2025 is to enter a collaboration with a clinical research organization (CRO) together with Solasia and to have a dialogue with the Japanese regulatory authority PMDA.

## Drug substance and IP enhancements

As a part of the life cycle management of arfolitixorin and aiming at continuously develop and further improve the drug substance as well as strengthening the international intellectual property protection in the long term, Isofol has expanded the long-standing collaboration with our drug substance partner to include further substance and formulation development. By this, we will be actively working on the development and evaluation of new compositions and formulations of the drug substance with the overall aim of further enhancing arfolitixorin and its patent protection.

## Operational update at investor meeting

At the end of November, we provided a comprehensive operational update during an investor meeting and presented the evidence platform that forms the basis for the design of our continued clinical development. Additionally, we provided an updated view on the commercial potential of arfolitixorin based on a new market analysis focusing on the crucial U.S. market. The evidence platform summarizes findings from analyses and preclinical results presented over the past year, demonstrating that arfolitixorin has proven efficacy in an extensive clinical Phase III-study, that higher doses of arfolitixorin administered through a new delivery method are expected to yield enhanced efficacy, and that these higher doses can likely be administered without compromising the safety profile. The new study design takes advantage of these insights and thus has better opportunities to evaluate the potential of arfolitixorin than the previously conducted global Phase III AGENT study.

According to a market analysis conducted by an external consultancy firm, the global market for treatment for metastatic colorectal cancer is expected to increase to SEK 80 billion by 2032. Current standard of care, 5-FU-based chemotherapy in combination with folate (like arfolitixorin), is expected to remain for the foreseeable future. The analysis confirmed Isofol's previous estimate that arfolitixorin, after a potential market launch, could reach block buster gross sales (over SEK 10 billion per year) in me-

tastatic colorectal cancer in the U.S. market alone. Further, we see opportunities in additional indication areas and in more geographic markets such as Japan and Canada where Isofol already has commercial partners, but also in other parts of the world – not least in Europe. The need for new treatments for metastatic colorectal cancer is global, and so is the geographical potential of arfolitixorin.

During the investor meeting, we had a guest appearance from the distinguished Professor Sebastian Stintzing, at Charité – Universitätsmedizin Berlin. In a video presentation, he highlighted the great medical need for new options in the first-line treatment of metastatic colorectal cancer and the anticipation he has for arfolitixorin. There was no mistaking his strong commitment to our development collaboration and to improving the outlook for patients by fostering research and development of new treatments. The investor meeting is available to watch on Isofol's website.

## Modelle study published

During the quarter, the results from the investigator-initiated study Modelle were published in the scientific paper BJC Reports. The study, conducted at Sahlgrenska University Hospital in collaboration with Norrland University Hospital with financial support from Isofol, evaluated the effect of arfolitixorin at tissue level. The study included 30 patients and evaluated different dose regimens of arfolitixorin and its ability to enhance the tumor inhibiting effect of 5-FU-based chemotherapy. The effect was measured as inhibition of thymidylate synthase (TS), the target enzyme of the treatment that drives tumor cell growth and is an important target in cancer treatment.

The Modelle study showed, among other things, a dose-dependent TS inhibition in the patients' liver metastases and complements other preclinical studies where surrogate markers have been used to measure TS inhibition – another important piece of the puzzle that supports the dose-response relationship of arfolitixorin and the hypothesis on which the development work is based.

## Scientific conferences and meetings with external stakeholders

As our strategy and clinical development plan materialize, we are seeing an increased interest from potential partners and other stakeholders when presenting Isofol and arfolitixorin at scientific conferences as well as partnering and investor meetings. During the last quarter of 2024, we presented a late-breaking abstract at ENA in Barcelona, showing the dose-response relationship of arfolitixorin. We also participated in BIO Europe, this year taking place in Stockholm. In early 2025, we attended the JP Morgan Healthcare Conference in San Francisco – a comprehensive and informative investor symposium connecting global pharma, high-growth innovative companies and investors. At the end of January, an abstract was also presented, summarizing the findings of the post hoc analysis of the completed Phase III AGENT study at ASCO-GI in San Francisco, USA.

We move beyond 2024 with strengthened conviction and renewed energy as we enter the next phase in the company's development: launching the clinical study.

Gothenburg, February 19, 2025

Petter Segelman Lindqvist
CEO, Isofol Medical AB (publ)

# Clinical development plan for arfolitixorin

Isofol is preparing to launch a clinical Phase Ib/II study evaluating the efficacy and safety of a new dosage regimen for our drug candidate arfolitixorin as a new potential treatment for metastatic colorectal cancer. The study will be initiated during the spring at the prominent academic hospital Charité – Universitätsmedizin Berlin, with a potential expansion to Japan planned for next year.




*Preliminary clinical study design*

During 2024, Isofol generated key data that, combined with existing evidence, strengthens the scientific rationale for the continued development of arfolitixorin – one of few innovations with the potential to enhance the efficacy of first-line metastatic colorectal cancer treatment. The evidence platform gathers comprehensive data on arfolitixorin generated in preclinical and clinical studies and the conclusions can be summarized as follows: Arfolitixorin has already shown efficacy in an extensive clinical Phase III-study; higher doses administered through a new regimen are expected to yield enhanced efficacy; and that these higher doses can likely be administered without compromising the safety profile.

The supporting data for these claims has been presented in press releases throughout 2024, and collectively, the evidence platform reinforces the company's conviction that the new study design offers better opportunities to demonstrate the potential of arfolitixorin compared to the previously conducted Phase III-study.

## New clinical study

Isofol has submitted a CTA (Clinical Trial Application) to start a clinical Phase Ib/II-study to the German regulatory authority, BfArM, and expects to be able to initiate the first part of the study during the spring. At year-end, the company received positive feedback from the authority, and final adjustments are now being implemented to establish the definitive design of the dose cohorts. The new study will evaluate how effectively the drug candidate performs when given at optimized doses alongside 5-FU-based chemotherapy in patients with metastatic colorectal cancer. The study aims to generate efficacy and safety data ahead of the continued clinical development. To achieve an indication of improved efficacy compared with the current standard treatment (5-FU-based chemotherapy with leucovorin), comparable analyses will be made against historical control data, for example with our own Phase III-study data.

The study will be carried out in two phases, where the introductory Phase Ib part will evaluate escalating doses. The highest tolerated dose will then be compared with a lower dose and further evaluated in the following Phase II part of the study, with a focus on evaluating efficacy. Interim analyses will be carried out in the Phase II part in order to wind down the arm that potentially demonstrates inferior efficacy and/or toxicity. The study will be conducted in collaboration with Charité – Universitätsmedizin Berlin, one of Europe's leading cancer hospitals.


## Study expansion to Japan

At the end of 2024, our Japanese partner Solasia made a strategic decision to actively participate in the second part of the study with the aim of enrolling patients in Japan during 2026. In parallel with the initiation of the first phase with Charité, Isofol and Solasia will jointly prepare for the expansion of the study to Japan. The inclusion of Japanese patients means an increased number of patients and diversifies the patient population, creating better conditions for future regulatory processes both in Japan and in other markets.

## Clinical development in collaboration with partners

To optimize the completion of the clinical study and to maximize the possibility of its success, the company is conducting clinical development in collaboration with existing partners including, in addition to Charité – Universitätsmedizin Berlin and Solasia, Merck KGaA, as well as selected suppliers and partners.

# Financial information, October-December

## COMPARISON BETWEEN THE FOURTH QUARTER OF 2024 AND 2023

Amounts stated without parentheses refer to the October-December 2024 period, and amounts stated in parentheses refer to October-December 2023.

### REVENUE

#### Operating revenue

Net revenue amounted to kSEK 0 (0) during the period.

### OPERATING COSTS

#### Other external costs

Other external costs amounted to kSEK -10,651 (-9,212), corresponding to an increase of kSEK 1,439. Costs during the quarter are primarily attributable to start-up costs for future studies related to clinical CRO, advisory services and consulting resources pertaining to drug development and administration, along with other ongoing operating expenses. The year-earlier period was impacted by costs mainly related to laboratory studies of arfolitixorin.

#### Personnel costs

Personnel costs amounted to kSEK -3,401 (-925), corresponding to an increase of kSEK 2,476. The increase is partly due to that the number of people has increased but also due to variable remuneration related to 2024. There were five (three) employees at the end of December 2024.

#### Depreciation and amortization

Depreciation, amortization and impairment of tangible and intangible fixed assets during the period amounted to kSEK 0 (-1).

#### Financial items

Financial revenue amounted to kSEK 608 (1,260), attributable to interest income in cash and cash equivalents. Financial costs amounted to kSEK 0 (-10).

### RESULT

The operating result amounted to kSEK -13,710 (-10,133), corresponding to an increased loss of kSEK 3,577. The result after financial items amounted to kSEK -13,102 (-8,883), corresponding to an increased loss of kSEK 4,219. The Group has no tax costs since there was no profit in the period.

### CASH AND CASH EQUIVALENTS

The company's cash and cash equivalents as of September 30, 2024 amounted to kSEK 96,157 (138,148). No loans had been taken up as of December 31, 2024 or have been taken up since then. SEK 0 (0) has been pledged as collateral from cash and cash equivalents.

### CASH FLOW

#### Cash flow from operating activities

Cash flow from operating activities during the period amounted to kSEK -8,282 (-6,076), corresponding to a change of kSEK 2,206. The negative cash flow is primarily attributable to start-up costs for future studies related to clinical CRO, advisory services, consulting costs for drug development and administration, and personnel costs.

#### Cash flow from investing activities

Cash flow from investing activities during the period amounted to kSEK 0 (50).

#### Cash flow from financing activities

Cash flow from financing activities during the period amounted to kSEK 0 (0).

#### Cash flow for the period

Cash flow for the period amounted to kSEK -8,282 (-6,025), corresponding to a change of kSEK 2,257.

### INVESTMENTS

The investments during the period amounted to kSEK 0 (0). Most of the company´s costs are related to research and development. These costs are expensed on an ongoing basis and are thus not classified as investments. The company has no material ongoing or planned investments.

# Financial information, January-December

## COMPARISON BETWEEN JANUARY TO DECEMBER 2024 AND 2023

Amounts stated without parentheses refer to January-December 2024, and amounts stated in parentheses refer to January-December 2023.

### REVENUE

#### Operating revenue

Net revenue amounted to kSEK 0 (721) during the period.

### OPERATING COSTS

#### Other external costs

Other external costs amounted to kSEK -38,734 (-35,136), corresponding to an increase of kSEK 3,598. Costs during the year are primarily attributable to start-up costs for future studies related to clinical CRO, advisory services and consulting resources pertaining to drug development and administration, along with other ongoing operating expenses. The year-earlier period was strongly impacted by costs related to wind-up activities and analyses related to the AGENT study in accordance with the strategy presented at that time.

#### Personnel costs

Personnel costs amounted to kSEK -8,480 (-7,424), corresponding to an increase of kSEK 1,056. There were five (three) employees at the end of December 2024.

#### Depreciation and amortization

Depreciation, amortization and impairment of tangible and intangible fixed assets during the period amounted to kSEK -3 (-37).

#### Financial items

Financial revenue amounted to kSEK 3,721 (4,622), attributable to interest income in cash and cash equivalents. Financial costs amounted to kSEK 0 (-10).

### RESULT

The operating result amounted to kSEK -47,209 (-41 683), corresponding to an increased loss of kSEK 5,526. The result after financial items was kSEK -43,488 (-37,071), corresponding to an increased loss of kSEK 6,417. The company has no tax costs since there was no profit in the period.

### CASH AND CASH EQUIVALENTS

The company's cash and cash equivalents as of December 31, 2024 amounted to kSEK 96,157 (138,148). No loans had been taken up as of December 31, 2024 or have been taken up since then. SEK 0 (0) has been pledged as collateral from cash and cash equivalents.

### CASH FLOW

#### Cash flow from operating activities

Cash flow from operating activities during the period amounted to kSEK -41,986 (-52,536), corresponding to a change of kSEK 10,550. The negative cash flow is primarily attributable to start-up costs for future studies related to clinical CRO, advisory services, consulting costs for drug development and administration, and personnel costs.

#### Cash flow from investing activities

Cash flow from investing activities during the period amounted to kSEK 0 (101).

#### Cash flow from financing activities

Cash flow from financing activities during the period amounted to kSEK 0 (0).

#### Cash flow for the period

Cash flow for the period amounted to kSEK -41,986 (-52,435), corresponding to a change of kSEK 10,449.

### INVESTMENTS

The investments during the period amounted to kSEK 0 (0). Most of the company´s costs are related to research and development. These costs are expensed on an ongoing basis and are thus not classified as investments. The company has no material ongoing or planned investments.

# Other information

## ORGANIZATION AND EMPLOYEES

There were five (three) full-time employees at the end of the reporting period, of whom one man and four women, all employed at the company's head office in Gothenburg, Sweden. In addition, the company has a number of consultants in important key functions who work full-time or almost full-time for Isofol.

## INFORMATION ABOUT TRANSACTIONS WITH RELATED PARTIES

Transactions with related parties take place on market terms.

Since the end of Roger Tell's employment in June 2023, Isofol has had a consultancy agreement with a company owned by Roger for medical consultancy services as well as a consultancy agreement as acting CEO of Isofol. The agreement for medical consultancy services was terminated in connection with Roger taking office as acting CEO, and a new agreement was signed with the same company for the CEO assignment. In January 2024, Roger's CEO consultancy agreement was replaced with a consultancy agreement for medical advisory services in the role as Chief Medical Officer, and in the fourth quarter of 2024 remuneration of SEK 750,000 was paid for CMO services.

Remuneration to the company's senior executives was paid according to applicable policies and guidelines during the year.

## SIGNIFICANT RISKS AND UNCERTAINTY FACTORS

Isofol's main business is the research and development of one drug, arfolitixorin. This business is capital-intensive and associated with risk. Isofol's operations are associated with risks that could have a material negative impact on the company's operations, financial position and result. The risks that are considered to be of special significance in regard to Isofol's future development are linked to the availability of the financial and clinical resources to conduct the company's clinical activities.

Isofol works continuously to identify, evaluate and manage risks in various systems and processes. Risk analyses are conducted on an ongoing basis for the business, but also for activities that lie outside Isofol's normal quality system.

The most significant strategic and operational risks that affect the company are described in the 2023 Annual Report. The company's assessment is that there have been no material changes to these risks and uncertainties as of December 31, 2024.

## ISOFOL'S SHARE

The number of shares at the end of the period was 161,515,440 (161,515,440), with a nominal value of SEK 0.0306 (0.0306). The average number of shares in the third quarter was 161,515,440 (161,515,440). Since 2021, the share is listed on Nasdaq Stockholm's main list, under the commercial name "ISOFOL" and ISIN SE0009581051.

### Largest shareholders at December 31, 2024

| Shareholder | Number of shares | Share capital/votes |
|---|---|---|
| Avanza Pension | 14,368,280 | 8.90% |
| Swedbank Försäkring | 7,911,911 | 4.90% |
| Christian Haglund | 7,636,506 | 4.73% |
| Göran Gustafsson* | 6,003,489 | 3.72% |
| Mats Franzén med närstående* | 5,952,393 | 3.69% |
| Hans Enocson | 4,555,236 | 2.82% |
| Handelsbanken Fonder | 4,386,104 | 2.72% |
| Bengt Gustafsson | 3,749,459 | 2.32% |
| Claes Ekman | 3,302,511 | 2.04% |
| Futur Pension | 2,135,150 | 1.32% |
| **10 largest shareholders** | **60,001,039** | **37.15%** |
| Other shareholders | 101,514,401 | 62.85% |
| **TOTAL** | **161,515,440** | **100.00%** |

** Own or related natural or legal person's holding of shares (direct and indirect) and other financial instruments in the company.*

SOURCE: MONITOR OF MODULAR FINANCE AB. COMPILED AND PROCESSED DATA FROM SOURCES INCLUDING EUROCLEAR, MORNINGSTAR AND THE SWEDISH FINANCIAL SUPERVISORY AUTHORITY.

## EVENTS AFTER THE END OF THE REPORTING PERIOD

No significant events other than those stated on page 1 have occurred since the end of the reporting period.

## FORWARD-LOOKING INFORMATION

Even if the available data appears to be positive, there can be no guarantee that the clinical studies that the company intends to carry out will be successful. Consequently, actual future outcomes may differ significantly compared with what is stated in the forward-looking information, depending on factors including changed conditions in the economy and the market, changes in legal and regulatory requirements as well as political measures.

## AUDIT REPORT

This report has not been reviewed by the company's auditors.

## ANNUAL GENERAL MEETING 2025

The Annual General Meeting of Isofol Medical AB (publ) is scheduled to be held on May 21, 2025, in Gothenburg. Shareholders who wish to have a matter addressed at the meeting may submit a written request to the Board of Directors. Such requests for agenda items should be sent to Isofol Medical AB, Attn: Chairman of the Board, Arvid Wallgrens Backe 20, 413 46 GOTHENBURG, Sweden, or via email to arsstamma@isofolmedical.com. Requests must be received by the Board no later than seven weeks before the meeting or sufficiently in advance to allow the matter to be included in the notice of the meeting if required.

### Nomination Committee for the Annual General Meeting

The Nomination Committee for the 2025 Annual General Meeting consists of Johan Möller (Chairman), Christian Haglund, Göran Gustafsson and Lars Lind. Any proposals must be submitted to the Nomination Committee by February 28, 2025, to be included in the notice and agenda for the 2025 Annual General Meeting. Shareholders who wish to submit proposals to Isofol's Nomination Committee may do so by contacting Isofol Medical AB, Attn: Nomination Committee, Arvid Wallgrens Backe 20, 413 46 GOTHENBURG, Sweden, or via email to valberedning@isofolmedical.com.

## FINANCIAL REPORTS

Major fluctuations in revenue and costs for various periods may occur due to the nature of the business. Revenue is not seasonal or regular in any other way; instead, it is partly related to when milestones that generate remuneration are achieved in licensed research projects. Exactly as with revenue, costs may fluctuate between different periods. This is affected by the phases that various projects are in since some phases generate more costs. Figures in parentheses indicate the outcome for the corresponding period in the preceding year for items related to the income statement and cash flow. Amounts are stated in kSEK unless otherwise specified. All stated amounts are rounded, which means that some totals may occasionally appear to be incorrect as a result.

## FINANCIAL CALENDAR

Isofol intends to publish financial reports and hold meetings according to the following schedule:

| | |
|---|---|
| Annual report 2024 | week 15 in April, 2025 |
| Interim report January-March 2025 | May 21, 2025 |
| Annual General Meeting 2025 | May 21, 2025, Gothenburg |
| Interim report April-June 2025 | July 18, 2025 |
| Interim report July-September 2025 | November 12, 2025 |
| Year-end report 2025 | February 18, 2026 |

The interim reports are published on the company's website, and updates about upcoming events take place continuously at www.isofolmedical.com.

# For further information

**Petter Segelman Lindqvist, CEO**
Phone: +46 (0)739 60 12 56
E-mail: petter.s.lindqvist@isofolmedical.com

**Margareta Hagman, CFO**
Phone: +46 (0)738 73 34 18
E-mail: margareta.hagman@isofolmedical.com

**Isofol Medical AB (publ)**
Biotech Center
Arvid Wallgrens Backe 20
413 46 Gothenburg, Sweden

www.isofolmedical.com | info@isofolmedical.com
Corporate identity number: 556759-8064 | Registered office: Gothenburg

This report has been prepared in a Swedish original and has been translated into English. In the event of differences between the two, the Swedish version shall apply.

# Income statement

| kSEK | Note | 2024 Oct-Dec | 2023 Oct-Dec | 2024 Jan-Dec | 2023 Jan-Dec |
|---|---|---|---|---|---|
| OPERATING REVENUE | | | | | |
| Net revenue | 2 | - | - | - | 721 |
| **Total operating revenue** | | **-** | **-** | **-** | **721** |
| | | | | | |
| OPERATING COSTS | | | | | |
| Other external costs | | -10,651 | -9,212 | -38,734 | -35,136 |
| Personnel costs | | -3,401 | -925 | -8,480 | -7,424 |
| Depreciation | | - | -1 | -3 | -37 |
| Other operating costs* | | 343 | 5 | 8 | 192 |
| **Total operating costs** | | **-13,710** | **-10,133** | **-47,209** | **-42,405** |
| **Operating result** | | **-13,710** | **-10,133** | **-47,209** | **-41,683** |
| | | | | | |
| FINANCIAL ITEMS | | | | | |
| Financial revenue | | 608 | 1,260 | 3,721 | 4,622 |
| Financial costs | | - | -10 | - | -10 |
| **Total financial items** | | **608** | **1,250** | **3,721** | **4,612** |
| **Result after financial items** | | **-13,102** | **-8,883** | **-43,488** | **-37,071** |
| | | | | | |
| **Profit before tax** | | **-13,102** | **-8,883** | **-43,488** | **-37,071** |
| Tax on result for the period | | - | - | - | - |
| **Result** | | **-13,102** | **-8,883** | **-43,488** | **-37,071** |
| Attributable to: | | | | | |
| Company's shareholders | | -13,102 | -8,883 | -43,488 | -37,071 |
| | | | | | |
| EARNINGS PER SHARE | | | | | |
| Before dilution (SEK) | | -0.08 | -0.05 | -0.27 | -0.23 |
| After dilution (SEK) | | -0.08 | -0.05 | -0.27 | -0.23 |

* Refers to currency effects associated with the business.

There are no amounts to be recognized as other comprehensive income, which is why the result for the period/year corresponds to comprehensive income for the period/year.

# Balance sheet

| kSEK | Note | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| ASSETS | | | |
| FIXED ASSETS | | | |
| Intangible fixed assets | | | |
| Patents, licenses and similar rights | | - | - |
| **Total intangible fixed assets** | | **-** | **-** |
| | | | |
| Tangible fixed assets | | | |
| Equipment, tools and right-of-use assets | | - | 3 |
| **Total tangible fixed assets** | | **-** | **3** |
| | | | |
| Financial fixed assets | | | |
| Participations in Group companies | | - | - |
| **Total financial fixed assets** | | **-** | **-** |
| **Total fixed assets** | | **-** | **3** |
| | | | |
| CURRENT ASSETS | | | |
| Accounts receivable | | - | - |
| Other receivables | 3 | 1,806 | 2,145 |
| Prepaid expenses and accrued income | | 454 | 301 |
| Cash and cash equivalents | 3 | 96,157 | 138,148 |
| **Total current assets** | | **98,417** | **140,594** |
| **Total assets** | | **98,417** | **140,597** |

# Balance sheet

| kSEK | Note | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| EQUITY AND LIABILITIES | | | |
| EQUITY | | | |
| Restricted equity | | | |
| Share capital | | 4,945 | 4,945 |
| **Total restricted equity** | | **4,945** | **4,945** |
| | | | |
| Non-restricted equity | | | |
| Share premium reserve | | 1,218,276 | 1,218,276 |
| Retained earnings | | -1,101,789 | -1,064,718 |
| Result for the year | | -43,488 | -37,071 |
| **Total non-restricted equity** | | **73,000** | **116,488** |
| **Total equity** | | **77,945** | **121,433** |
| | | | |
| LIABILITIES | | | |
| Long-term liabilities | | | |
| Other provisions | 4 | 648 | 910 |
| **Total long-term liabilities** | | **648** | **910** |
| | | | |
| Current liabilities | | | |
| Accounts payable | 3 | 2,028 | 1,988 |
| Other liabilities | 3 | 976 | 1,232 |
| Accrued expenses and deferred income | 3 | 16,821 | 15,033 |
| **Total current liabilities** | | **19,824** | **18,253** |
| **Total liabilities** | | **20,472** | **19,164** |
| **Total equity and liabilities** | | **98,417** | **140,597** |

# Statement of changes in equity

| | Restricted equity | Non-restricted equity | | |
|---|---|---|---|---|
| **kSEK** | **Share capital** | **Share premium reserve** | **Retained earnings** | **Total equity** |
| Opening balance, Jan 1, 2023 | 4,945 | 1,218,276 | -1,064,718 | 158,504 |
| **Result for the period** | **-** | **-** | **-37,071** | **-37,071** |
| **Equity, Dec 31, 2023** | **4,945** | **1,218,276** | **-1,101,789** | **121,433** |
| | | | | |
| Opening equity, Jan 1, 2024 | 4,945 | 1,218,276 | -1,101,789 | 121,433 |
| **Result for the period** | **-** | **-** | **-43,488** | **-43,488** |
| **Equity, Dec 31, 2024** | **4,945** | **1,218,276** | **-1,145,277** | **77,945** |

# Cash flow statement

| kSEK | 2024 Oct-Dec | 2023 Oct-Dec | 2024 Jan-Dec | 2023 Jan-Dec |
|---|---|---|---|---|
| **OPERATING ACTIVITIES** | | | | |
| Result after financial items | -13,102 | -8,883 | -43,488 | -37,071 |
| Adjustments for non-cash items | 2,714 | -1,219 | -255 | -4,411 |
| Income tax paid | - | - | - | - |
| **Cash flow from operating activities before changes in working capital** | **-10,388** | **-10,102** | **-43,743** | **-41,482** |
| **CASH FLOW FROM CHANGES IN WORKING CAPITAL** | | | | |
| Increase (-)/decrease (+) in other current receivables | 681 | 4,696 | 186 | 21,233 |
| Increase (+)/decrease (-) in other current liabilities | 1,425 | -670 | 1,571 | -32,287 |
| **Change in working capital** | **2,106** | **4,026** | **1,757** | **-11,054** |
| **Cash flow from operating activities** | **-8,282** | **-6,076** | **-41,986** | **-52,536** |
| **INVESTING ACTIVITIES** | | | | |
| Acquisition of tangible fixed assets | - | - | - | 51 |
| Acquisition of financial fixed assets | - | 50 | - | 50 |
| **Cash flow from investing activities** | **-** | **50** | **-** | **101** |
| **FINANCING ACTIVITIES** | | | | |
| **Cash flow from financing activities** | **-** | **-** | **-** | **-** |
| Cash flow for the period | -8,282 | -6,025 | -41,986 | -52,435 |
| Cash and cash equivalents at the beginning of the period | 104,020 | 144,176 | 138,148 | 190,533 |
| Exchange rate difference in cash and cash equivalents | 420 | -3 | -5 | 50 |
| **Cash and cash equivalents at the end of the period** | **96,157** | **138,148** | **96,157** | **138,148** |

# Notes

## Note 1 Accounting principles

This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The company's financial statements have been prepared in accordance with the Swedish Annual Accounts Act and the Swedish Corporate Reporting Board's recommendation RFR 2 Accounting for legal entities. Disclosures in accordance with IAS 34 are provided in the notes and in other sections of the report.

New and amended standards adopted from 2024 are not expected to have any significant impact on the company's financial position.

The company does not apply IFRS 16 in accordance with the exception in RFR 2.

## Note 2 Net sales and operating segments

### NET SALES

Isofol's net revenue derives from licensing agreements for the licensing rights to Isofol's intellectual property. Revenue from licensing agreements may comprise one-off payments, licensing fees, royalties and milestone payments for the use of Isofol's intellectual property. Isofol may also be entitled under its licensing agreements to receive reimbursements for costs incurred for the execution of service assignments.

The company's revenue amounted to kSEK 0 (0) during fourth quarter.

### OPERATING SEGMENTS

The Group's operations comprise the development of the drug candidate arfolitixorin and are organized as a cohesive business within the framework of the development of the drug candidate and evaluation of the paths forward for arfolitixorin in accordance with the strategic plan that was presented on March 19, 2024. Accordingly, all of the company's operations comprise one operating segment. The operating segment is followed up in a manner that complies with the internal reporting submitted to the chief operating decision maker, namely the CEO. Only one segment is used in the internal reporting to the CEO.

## Note 3 Financial assets and liabilities

There are no significant differences between fair value and carrying amount in respect of financial assets and liabilities. Financial assets and liabilities are measured at amortized cost. As of the balance sheet date, the carrying amount of the Group's financial assets amounted to kSEK 96,157 (138,148) and financial liabilities to kSEK 17,321 (16,789).

As of December 31, 2024, the company had no financial instruments measured at fair value.

## Note 4 Provisions

In 2022, Isofol entered into an agreement with a supplier for purchases of packaging material for the potential future sale of arfolitixorin. Use of the material depends on an approval for the commercialization of arfolitixorin. The agreement contains a financial guarantee totaling EUR 75,963, in which Isofol commits to purchasing material for an equivalent amount. The provision was adjusted in the first quarter of 2024 since part of the material had been disposed of and the cost of EUR 20,527 was settled against the provision. Based on the study outcome, management deemed it likely that the financial guarantee will be triggered. After the adjustment, kSEK 648 – equivalent to a present value of EUR 55,436 – was recognized as a provision in the company's balance sheet. The cost of the provision was recognized in the company's balance sheet in 2022. The specific date for the remainder of the outflow is still undetermined, but it is expected that a settlement will be made within five years.

# Key figures and definitions

This report includes key figures that are not defined in IFRS, but are included in the report because management believes that this information allows investors to analyze the company's earnings trend and financial position. Investors should consider these key figures as a supplement to the IFRS financial information.

| kSEK | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
| Equity | 77 945 | 121 433 |
| **Total assets** | **98 417** | **140 597** |
| **Solvency** | **79,2%** | **86,4%** |
| | | |
| Working capital | 78 593 | 122 341 |

## Solvency
Solvency is calculated by comparing equity in relation to total assets and is thus a measure of the proportion of assets that are financed with equity.

## Equity
Equity consists of share capital, other contributed capital and retained earnings, including the company's result for the year.

## Working capital
Working capital consists of the Group's current assets less current liabilities.

## Earnings per share
The result for the period divided by the weighted average number of shares during the period, before and after dilution.

# The Board's certification

The Board of Directors and the CEO hereby affirm that the interim report provides a fair overview of the operations, financial position and result of the Group and the Parent Company and describes the material risks and uncertainties facing the Parent Company and the companies included in the Group.

**Gothenburg, February 19, 2025**

**Jan-Eric Österlund**
Chairman

**Lars Lind**
Board member

**Sten Nilsson**
Board member

**Helena Taflin**
Board member

**Alain Herrera**
Board member

**Petter Segelman Lindqvist**
CEO




# ARFOLITIXORIN

## A DRUG CANDIDATE FOR THE TREATMENT OF COLORECTAL CANCER

**ISOFOL MEDICAL AB (publ)** | Biotech Center | Arvid Wallgrens Backe 20 | SE-413 46 Gothenburg, Sweden | www.isofolmedical.com